A Billion Pill Poppers

Coster, Helen
July 2006
Forbes Asia;7/24/2006, Vol. 2 Issue 13, p86
The article focuses on the advantages of investing in the pharmaceutical industry in China. Analysts predict that the Chinese pharmaceutical market will grow by $24 billion by 2010. Most drugs produced in China are generics and are sold through hospitals. China Shineway has posted a revenue of $102 million in 2005.


Related Articles

  • Shineway tapas McCann for China sell. Liu, Christy // Media: Asia's Media & Marketing Newspaper;1/14/2005, p10 

    The article reports that Chinese medicine firm Shineway Pharmaceutical has tapped McCann Healthcare to handle communications responsibilities for three product lines, including a launch assignment. McCann's appointment is Shineway's first partnership with an international agency in its drive to...

  • CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED.  // Acquisdata Company SnapShot: China Shineway Pharmaceutical Group;9/11/2015, Issue 435, p1 

    The article focuses on the financial performance of China Shineway Pharmaceutical Group Ltd. for the period ended June 30, 2015 including the sale of its injection and soft capsule products, the interim dividend declared by the Board, its purchase and redemption of shares and its competitors.

  • China Shineway annual profit decreases.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p16 

    The article reports on the decline in the profit of China Shineway Pharmaceutical Group Ltd. in 2012.

  • PRESCRIPTION DRUGS. Bittar, Christine // Adweek Eastern Edition;4/21/2003, Vol. 44 Issue 16, pSR28 

    This article focuses on advertising investments made by various pharmaceutical companies in the U.S. for the year 2003. Direct-to-consumer (DTC) prescription drug advertising is leveling off for major media outlets, including network prime time.That's largely the result of a fairly lackluster...

  • US Faces Rising Pharmaceutical Trade Deficit.  // Chemical Market Reporter;12/8/2003, Vol. 264 Issue 20, pFR14 

    Looks at the emergence of Ireland as the leading source for pharmaceutical imports to the U.S. as it continues to attract investment from the drug industry. Impact of the surge in pharmaceuticals imports on the pharmaceutical trade deficit; Concern on the growth of life sciences imports.

  • THERE'S STILL GOLD IN THEM THAR PILLS. O'Reilly, Brian; Schlosser, Julie // Fortune;7/23/2001, Vol. 144 Issue 2, p58 

    Discusses the outlook for the growth of the pharmaceuticals industry. Effect of medical breakthroughs and aging baby-boomers on the industry; Reaction of investors to the pharmaceuticals industry; Decisions of major companies in the industry, including Novartis and Bayer; Popularity of...

  • Accelerating drug discovery. Kraljevic, Sandra; Stambrook, Peter J.; Pavelic, Kresimir // EMBO Reports;Sep2004, Vol. 5 Issue 9, p837 

    Provides some insights into the drug development process and its implications for the pharmaceutical industry. Investments in drug development in the U.S. and Europe; Issues on drug safety, quality and efficacy; Industrial costs and market trends.

  • Pharma turns to reformulation to maximize ROI.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p39 

    The article reports on a trend in maximizing return of investment for pharmaceutical companies through drug reformulation. Reformulation has several distinct aims, such as staving off generic incursion by extending the patent of a molecule through switching the patient-protected reformulation....

  • Transatlantic Mismatch. Hunter, David // Chemical Week;4/21/1999, Vol. 161 Issue 15, p3 

    Offers a look on the growth of the prescription drug industry. Drugs that help boost the revenue of the industry; Implication of the growth; Top suppliers of life science intermediates; Investments announced by Bayer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics